TTR amyloidosis Centogene, Alnylam Pharmaceuticals Partner on Biomarker Study of Transthyretin Amyloidosis The study, called TRAMmoniTTR, will longitudinally monitor the clinical status of both symptomatic and asymptomatic participants with variants in the TTR gene. Alnylam, 23andMe Partner on Free Family Testing Program for Hereditary ATTR Amyloidosis 23andMe customers who have one of three common variants identified in reports can choose six family members to receive health and ancestry test kits. Akcea, Ambry Genetics to Launch Genetic Testing Program for ATTR Amyloidosis The effort will provide individuals with genetic testing to determine if they have the disorder, and when necessary, with genetic testing counselling. Scripps Team Develops Peptide Probes for Diagnosing, Monitoring Amyloidosis Premium The probes let researchers analyze oligomeric aggregates linked to forms of amyloidosis and could aid early diagnosis or monitoring response to therapy. Invitae, Alnylam to Provide Free Genetic Testing for Rare Amyloidosis Condition Through this Alnylam-funded program, Invitae will perform free testing for US patients suspected to have hereditary ATTR amyloidosis or a family history of it. Feb 13, 2015 Alnylam Aims to Release Multi-program Clinical Data in 1H 2015 Premium Nov 17, 2014 Alnylam Releases Phase II Data on ATTR Drug, Views Adverse Events as Non-issue Premium Nov 6, 2014 Alnylam Completes Enrollment in Phase II Trial of ATTR Drug Premium Oct 16, 2014 Alnylam Stock Jumps on Positive Phase II ATTR Drug Data Premium Oct 16, 2014 Arcturus Touts Dosing, Specificity of ATTR Drugs as They Move Toward Clinic Premium Sep 25, 2014 Alnylam Kicks Off TTR Amyloidosis Screening Study Premium Aug 14, 2014 Alnylam May Seek Approval for TTR Amyloidosis Rx in 2017 as Other Programs Advance Premium May 1, 2014 Alnylam Presents New Phase II, Preclinical Data from TTR Amyloidosis Programs Premium Apr 3, 2014 Alnylam ATTR Drug Receives Orphan Drug Status in Europe Premium Feb 27, 2014 Arcturus Releases Data Showing Potential of Delivery Technology for CRISPR Drugs Premium Aug 15, 2013 Alnylam Execs Highlight Conjugate Delivery Tech as Lipid-Enabled TTR Drug Advances Premium Jul 11, 2013 Alnylam Releases Positive Top-line Data on Subcutaneous TTR Amyloidosis Drug Premium Jul 3, 2013 Alnylam Reports Positive Phase II Data on TTR Drug, Aims for Phase III by Year End Premium Feb 14, 2013 Alnylam Loses Cubist as RSV Partner, Stays Focused on ATTR Programs Premium Jan 3, 2013 Oligo Drugs Advance in the Clinic in 2012 as Delivery Hurdles are Addressed Premium Dec 13, 2012 Isis TTR Amyloidosis Drug Fast Tracked by FDA Premium Oct 25, 2012 Isis to Receive $1.1M from Alnylam Premium Aug 2, 2012 Alnylam Shares Still Flying on ATTR Results, But Not All RNAi Drug Firms Get as Big a Boost on Data Premium Jul 19, 2012 Alnylam Reports Positive Phase I Data on ATTR Drug; Sees Pfizer Drug Setback as FDA Guide Premium Jun 21, 2012 Alnylam Receives Orphan Drug Status for Amyloidosis Drug Premium Load More Breaking News Bio-Rad Laboratories Q2 Revenues Climb 33 Percent, Beat Estimates Veracyte Q2 Revenues More Than Double on Test Volume Spike Increased Testing Revenues Boost Opko Health Q2 Revenues 47 Percent Qiagen Q2 Revenues Grow 28 Percent CareDx Q2 Revenues Up 77 Percent Secondary Genetic Findings Often Requested if Given Second Chance, Study Finds The Scan Booster Push New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high. With Help from Mr. Fluffington, PurrhD Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic. Man Charged With Threatening to Harm Fauci, Collins The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials. Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.